ALGS
Aligos Therapeutics, Inc.·Healthcare
8.00
0.693%(+0.06)
Market ClosedLast Updated: — ET
52W L: $4.1352W H: $13.69
ALGS NEWS
globenewswire.com
Mar 5
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2025.
globenewswire.com
Feb 26
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's fourth quarter 2025 financial results on Thursday, March 5, 2026, before the open of the U.S. financial markets.
globenewswire.com
Feb 23
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), being held February 22 – 25, 2026 in Denver, Colorado.
globenewswire.com
Jan 30
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 81,100 shares of the Company's stock (the “Inducement Grant”) to newly hired employees on January 29, 2026 (the “Grant Date”), in connection with the commencement of employment.
globenewswire.com
Jan 21
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus (HBV) infection.
